GlassScriptPhysician profile
Emily A Flowers
NPI 1932449121
$2,361.17
in general payments reported to CMS, 2019-2025
30 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $749 · 2022: $706 · 2023: $794 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $905.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $537.57 | 2021-2023 | |
| Novo Nordisk INC | $216.23 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $189.58 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $146.19 | 2021-2023 | |
| Amgen INC. | $145.28 | 2022-2023 | Prolia, Evenity |
| Janssen Pharmaceuticals, INC | $132.18 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.44 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $104.94 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.18 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $76.71 | 2021-2025 | Airsupra |
| Otsuka America Pharmaceutical, INC. | $72.12 | 2021-2023 | Abilify Maintena, Rexulti |
| Exact Sciences Corporation | $67.13 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $65.04 | 2023 | Auvelity |
| Ironshore Pharmaceuticals INC. | $43.20 | 2021-2023 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $42.08 | 2022-2023 | Quviviq |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $34.96 | 2022-2023 | |
| Dexcom, INC. | $32.24 | 2022-2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $28.09 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.26 | 2021 | |
| Merck Sharp & Dohme LLC | $25.34 | 2021-2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Genzyme Corporation | $24.84 | 2021 | |
| Astellas Pharma US INC | $22.40 | 2023 | Myrbetriq |
| Corium, LLC | $21.72 | 2022 | |
| Medtronic, INC. | $21.39 | 2025 | Inceptiv |
| Biohaven Pharmaceutical Holding Company LTD. | $19.30 | 2022 | |
| Alkermes, INC. | $16.79 | 2023 | Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $16.76 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.13 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.74 | 2022 | |
| Amarin Pharma, INC. | $12.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Flowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.